Background: The concept of an altered collective gut microbiota rather than identi-
| INTRODUCTION
The gut microbiota comprises a large collection of microbes and the largest within the body, reaching 10 12 cells/g of luminal contents in the colon. 1 In healthy individuals, it is dominated by 2 major bacterial phyla: Bacteroidetes and Firmicutes, with smaller representation from Proteobacteria and Actinobacteria. 2, 3 We are relatively ignorant of the functional and structural contributions of microorganisms outside of gut bacteria, with only a handful of publications looking at the gut virome (viruses and bacteriophages), mycome (fungi) and other micro-eukaryotes including protozoa. [4] [5] [6] The gut microbiota performs a number of crucial functions for the host including priming the immune system, breakdown of dietary substrates inaccessible to host enzymes, and detoxification of xenobiotics. 7 The healthy gut microbiome exhibits considerable functional diversity and possesses far greater genomic potential compared to its host. Perhaps of most interest, it is inherently modifiable. The implication of this interplay between humans and microbes is that pharmacological therapies, nutrient modifications and associated interventions that are targeted at the host will also significantly impact on the gut microbiota.
Genome-wide association studies (GWAS) have now identified 235 inflammatory bowel disease (IBD)-associated susceptibility loci, substantially expanding our understanding of the biology underlying these diseases. 8, 9 Early genetic studies focused on searching protein coding sequences, although it is now recognised that coding variation explains only~20% of genetic variation associated with IBD GWAS loci. 10 These studies highlighted the pivotal role of host:microbial interactions in IBD pathogenesis, specifically identifying T-cell activation, IL-23/T helper 17 pathway, autophagy and microbial recognition. [11] [12] [13] The most recent studies have undertaken low-coverage whole genome sequencing to interrogate low-frequency variants and define how much these variants contribute to IBD susceptibility. This approach has identified a missense variant in ADCY7, with mechanistic interpretation being that loss of function reduces cAMP production leading to an excessive inflammatory response that predisposes to ulcerative colitis but not Crohn's disease (CD). 8 
| DEFIN ING THE GUT MICROBIOTA IN INFLAMMATORY BOWEL DISEASE
A change in the normal gut microbiota with a shift away from host:microbial mutualism has been reported in many IBD studies; however, the vast majority of studies to date have focussed on bacterial changes and only recently has consideration of fungal and viral constituents been forthcoming. Some bacterial changes appear to be clearly linked to either CD or ulcerative colitis, while others appear to be attributed more generally to IBD. [14] [15] [16] [17] [18] [19] [20] The most consistent changes are reduction in biodiversity (lower number of species), with lower proportions of Firmicutes, consistently reported alongside increases in Proteobacteria 16, [21] [22] [23] [24] and Bacteroidetes phylum members 19 although reductions have also been reported. 15 Spatial re-organisation of Bacteroides species has also been documented with higher proportions of Bacteroides fragilis being seen in IBD patients. 20 In CD, changes in Firmicutes have particularly documented changes in Faecalibacterium prausnitzii. 25 Faecalibacterium prausnitzii levels have been consistently lower in ileal CD patients, although increases were noted in paediatric CD, potentially suggesting that further assessment is required. [26] [27] [28] Additional interrogation of F. prausnitzii has identified that F. prausnitzii populations are patient-specific and there are differing functional capabilities between strains with the tantalising potential that differing phylotypes may be having opposing effects. 28 Increases in Proteobacteria, especially Escherichia coli, including pathogenic variants, are also reported in ileal CD. 29 Changes in bacterial functional capabilities have been seen in ileal CD with alterations in bacterial carbohydrate metabolism, bacterial:host interactions and host secreted enzymes noted. 30 Perturbations to the structure of the gut microbiota, termed "dysbiosis," have also been shown to impart functional changes within the host creating a pro-inflammatory state. 31 More broadly, microbial functional changes associated with inflammatory bowel disease have identified enrichment in host metabolite uptake, oxidative stress tolerance and immune evasion, alongside decreases in microbial metabolism, including short chain fatty acid (SCFA) biosynthesis and amino acid biosynthesis. Put simply, the changes seen in gut microbial structure are associated with major metabolic impairments, which impart huge functional consequences to the host. Therefore, modulation of gut microbiota, through diet, antibiotics, prebiotics, probiotics and faecal microbiota transplantation (FMT), represent, at least theoretically, a promising therapeutic avenue for the management of inflammatory bowel disease, although available evidence suggest that fine tuning of our therapeutic offerings is still needed (Figure 1 ). 32 Being able to harness this potential is the fundamental basis of emerging therapeutic approaches to inflammatory bowel disease management, with microbial modulation becoming a major consideration in inflammatory bowel disease management over the last decade.
Potential drawbacks of most of the current literature, in terms of defining microbial changes in inflammatory bowel disease, are that studies have primarily reported on cohorts with established disease and they often fail to appreciate that mucosal and faecal microbiota are different. The confounding impact of therapeutic regimes (often complex and evolving), disease chronicity and also surgical intervention make it challenging to decipher whether taxonomic changes reflect disease-driven changes or are merely a response to a drastically altered intestinal environment. In order to address this a small number of studies looking at the microbiota of newly diagnosed patients have been published. The first study looked at mucosa-associated changes in newly diagnosed children (13 CD and 12 ulcerative colitis patients), all of whom were assessed at first presentation of active disease. However, importantly for microbiome analysis, the patients had not received systemic antibiotics or steroids in the 3 months prior to investigation or immunosuppression at any time. 33 Microbial diversity was significantly reduced in CD patients, compared to ulcerative colitis and control patients. 
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F I G U R E 1 Current microbial therapeutic mechanisms of action. Modulation of gut microbiota through diet, antibiotics, prebiotics, probiotics and faecal microbiota transplantation, which reflects the existing microbial therapeutic avenues for inflammatory bowel disease management. The evidence for use of the existing approaches depends on the type of disease present, with ulcerative colitis appearing to benefit most from approaches, such as faecal microbiota transplantation, which dramatically alters gut microbial community structure and function. Dietary modulation through exclusive enteral nutrition demonstrates success in paediatric Crohn's disease and is thought to work by reducing the bacterial diversity within the gut. Overall, however, the balance of evidence suggests that fine tuning of our therapeutic offerings is still needed T A B L E 1 Microbial alterations in IBD as determined by high-throughput sequencing. Only studies including 10 samples, relative to healthy controls. Reductions in the Firmicutes member F. prausnitzii were also noted, particularly in ileal CD. 40 Abnormalities in the intestinal microbiota have also been reported in ulcerative colitis, although to a lesser degree compared to CD. Less diverse microbiota profiles have been demonstrated in ulcerative colitis patient samples, and in particular, the finding of increased Clostridium perfringens in faeces suggests a role in disease exacerbation. 41 A decrease in Fusicatenibacter saccharivorans in patients with active ulcerative colitis has also been reported, in contrast to the increase observed in patients with quiescent disease. 42 
| THE ROLE OF THE VIROME
Newer methodological techniques in the metagenomic assessment of the gut virome as a composite entity has opened new avenues in our understanding of its role in the aetiopathogenesis of inflammatory bowel disease. Expansion of annotated viral databases and improved bioinformatic analysis have also increased the ability to correctly identify a larger cohort of these viruses. An initial study utilising epifluorescence microscopy was the first to suggest that there was an increase of bacteriophages in patients with CD as opposed to controls. 43 The predominant gut viruses identified were double-stranded DNA viruses in the Caudovirales order (including Podoviridae, Siphoviridae and Myoviridae). This finding was subsequently confirmed by a study utilising metagenomic assessment techniques on biopsy samples and gut washes in paediatric CD patients, wherein Wagner et al demonstrated that the maximum number of "viral hits" were seen in patients with CD. 44 Subsequently, a study by Wang et al looked at these changes in colonic biopsy samples from patients with CD and controls and showed alteration of virome abundance and diversity in the former group. 45 The study by P erez-Brocal was the first to document parallel changes between the bacterial and viral components of the gut microbiota in patients with inflammatory bowel disease. They demonstrated that there was a decrease in diversity and abundance of both the bacteria and viruses in patients with CD. 46 The most comprehensive analysis of the disease-specific alteration of the virome in IBD was reported by Norman et al. 47 The study demonstrated an expansion of Caudovirales bacteriophages in patients with both ulcerative colitis and CD but more importantly documented an inverse correlation with the bacterial component in both these diseases. However, the inverse relationship between the bacteria and the virome could not be reliably replicated in the validation USA cohorts in the study. 47 Subtle distinctions were noted between patients with CD and ulcerative colitis, wherein in the former group of subjects, the presence of Caudovirales were positively correlated with Enterobacteriaceae, Pasteurelloacaeae and Prevotellaceae but there was no such relationship noted with UC. P erez-Brocal also demonstrated the positive representation of Synechococcus phage S CBS1 and Retroviridae family of viruses in patients with CD, with this propensity suggesting that they could be potential biomarkers. Both these observations suggest that phenotypic differences in manifestations of ulcerative colitis and CD might be explained by the different changes in the gut virome. However, all these findings need to be consistently validated in other studies, and the bridge from association to causation still needs to be crossed.
| THE ROLE OF THE MYCOBIOME
Similar to virome analysis, fungi have long been suspected to play a role in IBD pathogenesis. Anti-Saccharomyces cerevisiae antibodies are well-known markers for CD. In mice, gut inflammation and antibiotic usage have been shown to promote fungal proliferation. 48 Other studies have shown that fungi can modulate susceptibility to inflammation in a negative (Candida albicans) or positive (Saccharomyces boulardii) manner. 49 Finally, mice lacking major genes involved in fungal sensing, such as Dectin-1 or Card9, have an increased fungal microbiota load and are more susceptible to colitis, with human genetic studies also confirming a role for CARD 9.
50,51
Recently, the pace of investigation has gathered momentum, although most clinical studies to date involve small patient cohorts and therefore lack definitive power.
Looking at fungal diversity, the consensus of findings indicates that the 2 major fungal phyla detected in the human gut are Ascomycota and Basidiomycota 50, [52] [53] [54] and that, numerically, fungal DNA is not a major constituent of the microbiome, with 99.1% of the genetic catalogue from the gut lumen being of bacterial origin, whereas fungal DNA accounts for around 0.02% of the entire mucosa-associated microbiota. [55] [56] [57] [58] Mukhopadhya et al were the first to look at the mycobiome in de novo paediatric inflammatory bowel disease patients and noted that there was an overwhelming predominance of the Basidomycota phylum in IBD patients, although sample size was limited, and each patient demonstrated a unique fungal signature. 4 Interestingly, the study was undertaken on mucosal biopsy samples rather than faecal samples. Higher levels of Basidiomycota were recently reported in mucosal biopsies from a treatment na€ ıve paediatric CD cohort from Saudi Arabia compared to control patients. 59 Interestingly, the mycobiome diversity analysis of faecal samples from the same cohort did not show the same fungal profile, highlighting similar findings to bacterial diversity studies which clearly demonstrate differing microbial consortia between mucosal and luminal samples. A mucosa-based study on 23 CD adult patients also demonstrated similar findings. 60 Sokol et al recently published a larger faecal-based adult inflammatory bowel disease study comprising 235 well-phenotyped inflammatory bowel disease subjects and 38 healthy subjects. 61 They identified a disease-specific fungal dysbiosis with shifts in composition involving the 2 dominant fungal phyla, and several fungal species including S. cerevisiae, Malassezia sympodialis and C. albicans.
Bacterial biodiversity was investigated and shown to decrease in both CD and ulcerative colitis; however, fungal biodiversity was decreased only in ulcerative colitis, indicating that a CD -specific gut environment may favour fungi at the expense of bacteria. They explored the equilibrium between bacterial and fungal diversity in the gut and determined that the fungi-to-bacteria diversity ratio was As well as being a potentially useful therapeutic intervention, there is evidence that suggests antibiotics play a role in the pathogenesis of inflammatory bowel disease, in particular CD, through development of dysbiosis. In the RISK study, an assessment of treatment-na€ ıve microbiomes of children with CD showed that the use of antibiotics increased the microbial dysbiosis associated with the background disease. 34 In a recent meta-analysis, antibiotic therapy was identified as a significant risk factor for the development of CD [92] [93] [94] In the same population setting, another single strain, Lactobacillus rhamnosus GG, achieved a longer time free from relapse than salicylates. 95 In few pilot studies, the probiotic yeast S. boulardii was effective both in inducing and in maintaining remission in subjects with mildto-moderately active ulcerative colitis. 96, 97 VSL#3, a probiotic mix of 4 Lactobacilli, 3 Bifidobacteria and a Streptococcus, is the product with the most available evidence to date. In a small sample of patients with ulcerative colitis unsuitable for salicylates, VSL#3 was found to be effective in maintenance of remission. 98 Moreover, VSL#3 has been shown to be effective in inducing remission in subjects with mild-to-moderately active ulcerative colitis, either combined with standard treatment 99 or alone. 100 In a meta-analysis, Other combinations of probiotic strains have not achieved results as consistent as those of VSL#3.
102-104
Several systematic reviews and meta-analyses tried to address the role of probiotics in the management of ulcerative colitis, without conclusive results. A Cochrane review showed probiotics were not more effective than placebo or active comparators in inducing the remission of active ulcerative colitis. 105 However, when only RCTs were pooled, probiotics were shown to be effective in the induction of remission (RR 1.80), although only VSL#3 was confirmed to achieve a significant advantage over placebo (RR 1.74) after analysis of strain subgroups. 106 A further Cochrane review found that probiotics were ineffective in the maintenance of remission in ulcerative colitis, 107 although a meta-analysis of RCTs showed their efficacy in the prevention of pouchitis. 108 Finally, 2 Cochrane reviews found that probiotics conferred no advantage over placebo in maintaining or inducing remission of CD. 118, 119 Therefore, probiotics are not suggested in the routine maintenance of remission in patients with CD. 79 The available evidence on the efficacy of prebiotics in CD is still poor. As suggested in a systematic review of RCTs, 120 further high-quality studies are needed to address the role of probiotics and prebiotics in the management of CD.
The disappointing results from probiotics to date are perhaps not surprising given that they were generally studied during a period with limited comprehension of, or ability to monitor, the microbiota in inflammatory bowel disease. Moreover, currently available probiotics were not rationally designed to correct the dysbiosis which can underlie the disease; therefore, any therapeutic effect from a single strain is a chance finding. Further study of targeted, specific probiotics informed by the modern microbial pathogenesis paradigm of inflammatory bowel disease is badly needed. The application of metagenomics may help to identify specific strains with biologically plausible efficacy in inflammatory bowel disease.
| Faecal microbial transplantation
Faecal microbiota transplantation is a medical treatment that involves the administration of faecal microbiota into the intestinal tract of a recipient. Various methods have been utilised for delivery of FMT, such as nasogastric tube, nasoduodenal tube, rectal enema, the biopsy channel of a colonoscope and more recently via entericcoated capsules. 121, 122 The optimal method of delivery remains unclear. The most researched and widely practiced form of FMT is allogenic and involves the transfer of faecal microbiota from a healthy donor into a patient. However, it should be noted that FMT can also be autologous in nature, 123 where faecal material is banked by a patient and reinstated a later date.
In modern medicine, FMT was first described in the literature in 1958 as a treatment for fulminant pseudomembranous colitis, where
Eiseman et al reported the successful treatment of 4 patients using FMT enemas. 124 Over the subsequent decades, there were several scattered case reports and case series of FMT for C. difficile infection (CDI), the majority of which were successful; however, there was still a lack of controlled clinical trial data for clinicians to reference. 125 In a landmark paper, van Nood et al published the first randomised control trial of FMT in C. difficile infection. 126 The effects were dramatic, with 81% of patients cured after a single FMT, given through nasoduodenal tube, compared with a cure rate of <31% in control groups. Since then, a large body of controlled and noncontrolled evidence has accumulated that reports a primary cure rate of 85%-90% in recurrent C. difficile infection where antibiotic treatment has failed. 127, 128 Although the mechanism of action of FMT in the treatment of C. difficile infection has yet to be fully defined, several theories have been put forward. These include direct activity against C.
difficile by the bacteria in the donated sample and restoration of secondary bile acid metabolism. 129 Interestingly, the notion that the bacteria in the donated sample play an indispensable role in the efficacy of FMT recently came into question in the light of a clinical case series that reported that sterile faecal filtrate was also effective in treating patients with C. difficile infection. from either a healthy donor or patients own stool. 142 The authors reported that there was no statistically significant difference in clinical or endoscopic remission between the 2 arms of the study.
Moayyedi et al allocated 75 patients to 6 FMT s, using stool prepared from a healthy donor or drinking water (placebo) via retention enema. 136 Patients who received FMT met the robust primary endpoint (clinical and endoscopic remission Mayo <3 with endoscopic Mayo 0) in a higher percentage of patients than placebo (24% vs 5%; P = .03). An interesting observation is that stool from 1 out of the 6 donors induced remission in 39% of patients, which was remarkably higher than the other donors (10%), suggesting that there may be a donor-patient compatibility effect for FMT in inflammatory bowel disease. Moayyedi et al reported that disease <1 year was also more associated with remission. However, the systematic review and meta-analysis performed by Costello et al found no association between disease duration and remission. Paramsothy et al randomly allocated 85 patients with active ulcerative colitis to receive either FMT or placebo (isotonic saline with added brown food colourant and odorant) administered once by colonoscopy, followed by 39 self-administered enemas over 8 weeks. 137 The faecal microbiota administered to patients was prepared from a mix of between 3 and 7 donors. The authors noted that this was a deliberate attempt to increase microbial diversity in each infusion and indeed increased diversity was confirmed using 16S amplicon Some bacteria such as F. prausnitzii, which have anti-inflammatory effects, are known to only survive in strictly anaerobic conditions and therefore may be lost over the course of aerobic processing. 148 There are several methodological differences between each trial that make it challenging to recommend an optimal protocol. However, taken collectively, the data from the randomised control trials that have been published to date suggest that distal administration, frequent dosing and use of diverse faecal microbiota could all be factors that could influence a positive response in ulcerative colitis.
Interestingly, a recent study of FMT in CD reported that frequent dosing was associated with increased efficacy. 149 Future research should investigate the efficacy and safety of capsule-delivered FMT in inflammatory bowel disease as this would be more suitable for frequent dosing and would simplify the design of placebo-controlled trials, though dose limitation may become a factor. 150 Across all studies FMT appear to be safe in the short term, with the majority of reported adverse events being mild, self-limiting and gastrointestinal in nature. 151 However, serious adverse events such as bacteraemia, perforations and death have been reported. Furthermore, there have been reported instances of flares, significant escalation of therapy and development of perianal disease in patients with concomitant inflammatory bowel disease and C. difficile infection treated with FMT. [152] [153] [154] Overall, the rate of serious adverse events appears to be higher in recipients of FMT through the upper gastrointestinal tract as a result of procedure-induced aspiration pneumonia. 151 The causality between nonprocedural adverse events and FMT has yet to be fully delineated and therefore further research from controlled trials is necessary to establish the factors involved. 151, 155 The long-term effects of FMT are yet to be established. However, as FMT involves the infusion of a largely uncharacterised active microbial suspension, there is a theoretical possibility that diseases linked to gut bacteria could be transferred. A description of the efficacy of exclusive enteral nutrition preceded any meaningful understanding of its mechanism of action, which has only recently begun to be understood with the advent of high-throughput, culture-free, microbial ecology tools. One early microbial study of exclusive enteral nutrition suggested either the low residue nature or potential prebiotic properties of the diet as potential modulators of the microbiome. 167 Recent data, however, demonstrate that the mechanism of action is paradoxical when compared to our understanding of CD pathogenesis. Exclusive enteral nutrition appears to reduce bacterial diversity further and reduces the proportion of key species, including F. prausnitzii, suggesting that its main mechanism of action is a reduction in the availability of bacterial substrate in the gut lumen (Figure 1 ). [168] [169] [170] [171] This offers the tantalising prospect of potentially identifiable key pathogenic organisms, which might be amenable to long-term remission by directed microbial therapy.
Limited data support the use of partial enteral nutrition as maintenance therapy for CD, with only 1 randomised control trial published to date describing a 35% relapse rate on half enteral nutrition vs 64% on free diet, over nearly 12-month follow-up, after induction of remission with exclusive enteral nutrition in 92%. 172 Unsurprisingly, the message of larger volumes of enteral formula being associated with higher rates of remission emerges from published work. 173 Although partial enteral nutrition is not thought to be effective as an induction agent in CD, 174 interest has turned recently to solid food alternatives to the socially challenging liquid-only exclusive enteral nutrition currently in use. Exploration of such strategies has the support of patients and their families. 175 Exciting work from Sigall-Boneh et al in Israel demonstrates proofof-principle of this approach, where a structured specific food elimination diet was used in children and adults with active CD, supplemented with 50% polymeric formula. 176 Remission rates were encouragingly high at~70%. The exact constituents of the diet were not reported, but it involved reduced exposure to animal fat, dairy, gluten and emulsifiers while allowing fruit-and vegetablederived fibre sources. It is difficult to comment on the potential mechanism of action without further dietary data, specifically regarding the substrate availability for colonic bacteria, particularly with regard to potential fibre and SCFA sources. Interestingly, 6/7 patients given the elimination diet without supplementary formula also entered remission, suggesting a "food-only" approach might achieve high efficacy rates. Other approaches and hypotheses for food-based CD therapy are discussed in detail in Lee et al. 177 Dietary emulsifiers are one area of significant interest that sit outside of the microbial substrate hypothesis, potentially opening avenues for increased pathogenic potential within the host microbiota. during and after treatment as well as robust randomised controlled trials will need to be performed to refine and improve on the evidence that is currently available.
The existing therapeutic approaches to modulate the gut microbiome are relatively unrefined and primitive ( Figure 2 ). However, looking forward, the future of microbiome modulating therapeutics looks bright. There are several novel strategies and technologies hurtling towards the clinic. In an effort to develop a more specific form of faecal microbial transplantation, many groups are pursuing single strains of live organisms or characterised communities of microbes ( Figure 2) . 180, 181 Other groups are taking an even more reductionist approach by mining bacteria for small molecules. 182 Finally, advances in the field of synthetic biology may mean that one day each of us will be able to colonise our gut with genetically modified bacteria that knock out "bad bugs" with bacteriophages or secrete antiinflammatory small molecules. Taken collectively, it is clear that ignoring the microbiome in inflammatory bowel disease is not an 
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F I G U R E 2 The future of microbiome-modulating therapeutics. Existing therapeutic approaches to modulate the gut microbiome are relatively unrefined and primitive, broadly falling into 3 categories, namely: accession (faecal microbiota transplantation and probiotics), reduction (antibiotics) or indirect modulation (exclusive enteral nutrition and prebiotics). Future therapeutic approaches will be more targeted and personalised to treat the underlying disease pathophysiology. Strategies that are currently being investigated include live biotherapeutics containing single strains or consortia of bacteria that have been rationally selected and bacteria that have been engineered to produce therapeutic proteins. Alongside this, developing personalised dietary manipulation strategies and small molecule delivery will also likely feature option and the current treatment paradigm is on course to change dramatically. 
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